

7th February 2018

(1) BSE Ltd
Listing Department,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai 400 001

(2) National Stock Exchange of India Ltd
Listing Department
Exchange Plaza, 5th floor,
Plot no. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai - 400 051

Scrip Code: 500087

Scrip Code: CIPLA EQ

(3) SOCIETE DE LA BOURSE DE LUXEMBOURG
Societe Anonyme
35A Boulevard Joseph II,
L-1840 Luxembourg


Dear Sirs,

Please find enclosed investor presentation dated 7th February 2018.

Kindly acknowledge the receipt.

Thank you,

Yours faithfully,
For Cipla Limited



Rajendra Chopra
Company Secretary

Encl: as above



Investor Presentation

Q3 FY 18

7th Feb 2018

Disclaimer



Except for the historical information contained herein, statements in this presentation and the subsequent discussions may constitute "forward-looking statements". These forward-looking statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially from those suggested by the forward-looking statements. These risks and uncertainties include, but are not limited to our ability to successfully implement our strategy, our growth and expansion plans, our ability to obtain regulatory approvals, technological changes, fluctuation in earnings, foreign exchange rates, our ability to manage international operations and exports, our exposure to market risks as well as other risks. Cipla Limited does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date thereof.

Information relating to any medical products or medical devices contained herein is provided by Cipla for general information purposes only. Information on any of the medical products or medical devices may vary from country-to-country. A reference to a medical product or a medical device does not imply that such medical product or medical device is available in your country. The commercial availability of the medical products or medical devices listed herein in your country is dependent on the validity and status of existing patents and/or marketing authorizations related to each. An independent enquiry regarding the availability of each medical products or medical device should be made for each individual country

The product information contained herein is not intended to provide complete medical information, and is not intended to be used as an alternative to consulting with qualified doctors or health care professionals.

Nothing contained herein should be construed as giving of advice or the making of a recommendation and it should not be relied on as the basis for any decision or action. It is important to only rely on the advice of a health care professional

Strong Growth Momentum across India, South Africa, Europe and API
Cost optimization across all spend lines driving strong EBITDA improvement

Financials Q3

Revenue Rs 3914 crs

7% vs. LY

[↑ ~10% vs LY on a like-to-like basis adjusted for GST]

EBITDA 20.9%

21% vs. LY

PAT 10.2%

25% vs. LY

[When adjusted¹ for one offs in the quarter]

Growth Continues Across Markets

India

13% vs. LY

On a like-to-like basis GST adj growth at ~ **22%**

South Africa

7% vs. LY

Highest ever quarterly sales

Europe

19% vs. LY

API

29% vs. LY

US Launches & R&D

Approval & Launch of Budesonide (gPulmicort) and Decitabine (gDacogen)

Q3 R&D: 7.6% of Sales


gAdvair: Clinical Trial on track
2 follow-on trials expected to begin soon

1. Adjusted for the impact of Deferred Tax accounting reflecting the changes in the US Tax rates and drop in value of intangibles

Q3 FY18 (Consolidated)

	Actuals (Rs Cr)	vs Q3 FY 17
Total Income from Operations	3,914	7%
a) Domestic Sales	1,632	12%
b) Int'l Sales	2,203	5%
c) Other Operating Income	79	-5%
EBITDA	819	21%
EBITDA %	20.9%	
PAT ²	401	7%/25% ³
PAT %	10.2%	

Revenue¹ Break-up



1 Others: Includes CNV business, Vet and others; SAGA includes South Africa, Sub-Saharan Africa and Cipla Global Access

2 PAT impacted by one-off related to drop in value of intangibles for US

3 Adjusted for the impact of Deferred Tax accounting reflecting the changes in the US Tax rates and drop in value of intangibles

Strong cash flow generation leading to continuous improvement in balance sheet health

Balance Sheet Health

In Rs crs

	Mar'17	Sept'17	Dec'17
Equity	12964	13679	14166
Net Debt	2651	2416	1888
Net Debt/Equity	0.20	0.18	0.13
Net Debt/EBITDA¹	1.07	0.92	0.68




¹ Trailing Twelve Months EBITDA

India (Rx + Gx) Sales



Q3 Y-o-Y


Rs Cr



On a like-to-like basis GST adj growth at ~22%

Q3 Q-o-Q

Rs Cr




Key Business Highlights¹

- Cipla out-performed the market (12% Vs Mkt 10%) with increase in market share by 10bps to 5.3%
- Key therapeutic areas delivered above market performance including Cardiac (12% Vs Mkt 7%), Anti-infective (14% vs 11%), Respiratory (14% Vs Mkt 12%), Derma (18% Vs Mkt 17%)
- Leveraging our commercial strength to build strategic partnerships with MNCs; launched 6 in-licensed products in YTD Dec'17
 - ❖ Improved ENT portfolio with launch of Rapid Rhino (nasal device)

¹ IMS Q3FY18


Q3 Y-o-Y

\$ Mn



Q3 Q-o-Q

\$ Mn




Key Business Highlights

- Approval received for Budesonide (gPulmicort) and Decitabine (gDacogen); Healthy contracted shares to help build stronger trajectory in the coming quarters
- Consistently ranked amongst the Top 10 most dispensed generic companies in the US
- Strong performance across key existing and new products
 - 13 of the 48^{1,2} (27% of portfolio) are in the leadership (#1) position.
 - 31 of 48 (65%) products ranked among top 3
- Filed 2 products in Q3FY18 taking the 9months count to 10 filings; expecting to file 10+ products in Q4

1 Market statistics as per IMS MAT Dec'17 | 2 Products covered under IMS

ANDA¹ Portfolio & Pipeline (As on 31st Dec'17)




1 Does not include Vet product ANDAs

2 PEPFAR approved ANDAs can be commercialised in US


Filings for under-development products in the US will bolster future growth

Split of top 50 projects


Therapy




Dosage form



Complexity



Market potential (innovator sales)



16 Para IV Filings primarily in Respiratory, Oncology and Dermatology

15+ limited competition products



CNS, Respiratory and Oncology pipeline has a **brand market size of >US\$ 25bn**

FPSM DPI under development for regulated markets

Of the 200+ development projects, top 50 have market size of > US\$ 35bn

Limited competition products – indicative only¹

1. Competition stats are Cipla estimates




Key Business Highlights

- South Africa (SA) business delivered its highest ever quarterly sales in history of R1.09bn growing ~7% vs last year in local currency; second consecutive quarter of record-breaking sales
- Above market growth in South Africa private market; As per IMS MAT Dec'17, Cipla grew ahead of the market at 11.1% in the private market vs 10.3% market growth
- Partnering efforts saw a significant boost with new launches coming from Anmarate acquisition and a deal with iNova (Valeant)
- Concluded a deal with Adcock Ingram to commercialise their comprehensive over the counter portfolio in Uganda and expand our footprint in Sub-Saharan Africa.

Emerging Markets¹

\$ Mn




- Strong in-market sales growth across key DTM markets
- FPSM in Australia gaining traction; targeting to increase market share in FY19
- Geo-political uncertainties in several Middle Eastern markets

impacting sales

1. Includes formulations business of markets other than US, India, SAGA and Europe

Europe


\$ Mn



- Strong growth momentum maintained with 19% growth for Q3 FY18
- Expanded respiratory franchise with approval for Beclomethasone in UK; first generic in the market
- Closed deal with Pharma S for sale of Croatian entity to further sharpen focus on select markets

API

\$ Mn



- Continued growth (29%) in Q3 over LY due to successful deliveries for Launch of Products with Key Customers
- Substantial increase in margins due to launch quantities supplied and product mix
- Improved traction in seedings and lock-ins with key customers

US

Limited competition portfolio launches on track; **10 ANDAs** filed in YTD Dec'17

India

Strong growth momentum continues with 10bps increase in market share; focus on in-licensing leading to new launches

South Africa

Highest ever quarterly sales reported in Q3FY18; Cipla grew ahead of the market at **11.1%** in private market

Specialty

Phase 1A study for Tizanidine patch progressing smoothly; in advanced stages of discussion for assets in Neurology and Respiratory

R&D

Advair trials progressing smoothly; two additional trials to begin soon

Thank you

Registered Office :

Cipla Limited, Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai 400 013

For any queries, please contact

Naveen Bansal

Investor.Relations@cipla.com

For more information please visit

www.cipla.com